Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC

NCT05375903 is registered in ClinicalTrials.gov with UroGen Pharma Ltd. as lead sponsor.

NCT NCT05375903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05375903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
Lead sponsor
UroGen Pharma Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 1, 2022
Completion date
January 9, 2026
Enrollment
51 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, carcinoma in situ of bladder, nmibc, non-muscle invasive bladder cancer, urothelial carcinoma bladder, urothelial carcinoma recurrent